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REVIEWMassively Parallel Sequencing:
The Next Big Thing in Genetic Medicine
Tracy Tucker,1,* Marco Marra,1,2 and Jan M. Friedman1,3Massively parallel sequencing has reduced the cost and increased
the throughput of genomic sequencing by more than three orders
of magnitude, and it seems likely that costs will fall and
throughput improve even more in the next few years. Clinical
use of massively parallel sequencing will provide a way to identify
the cause of many diseases of unknown etiology through simulta-
neous screening of thousands of loci for pathogenic mutations
and by sequencing biological specimens for the genomic signa-
tures of novel infectious agents. In addition to providing these
entirely new diagnostic capabilities, massively parallel sequencing
may also replace arrays and Sanger sequencing in clinical applica-
tions where they are currently being used.
Routine clinical use of massively parallel sequencing will require
higher accuracy, better ways to select genomic subsets of interest,
and improvements in the functionality, speed, and ease of use of
data analysis software. In addition, substantial enhancements in
laboratory computer infrastructure, data storage, and data transfer
capacity will be needed to handle the extremely large data sets
produced. Clinicians and laboratory personnel will require
training to use the sequence data effectively, and appropriate
methods will need to be developed to deal with the incidental
discovery of pathogenic mutations and variants of uncertain clin-
ical signiﬁcance. Massively parallel sequencing has the potential
to transform the practice of medical genetics and related ﬁelds,
but the vast amount of personal genomic data produced will
increase the responsibility of geneticists to ensure that the infor-
mation obtained is used in a medically and socially responsible
manner.
Introduction
DNA sequencing was ﬁrst described byMaxim andGilbert1
and Sanger et al. in 1977.2 Subsequent improvements to
the Sanger method have increased the efﬁciency and accu-
racy more than three orders of magnitude. At each step,
more sophisticated DNA sequencing instruments, pro-
grams, and bioinformatics have provided more automa-
tion and higher throughput. Several massively parallel
sequencing methods have become available in the last
couple of years, allowing larger-scale production of
genomic sequence, and the number of human genomes
sequenced with such instrumentation is now increasing
rapidly.3–6
As the cost of massively parallel sequencing falls, it
becomes feasible for smaller laboratories to adopt this tech-
nology, although doing so involves substantial initial
costs. These include not just the massively parallel
sequencing machines themselves, but also the associated142 The American Journal of Human Genetics 85, 142–154, Augustcosts of data storage and analysis. Massively parallel
sequencing has had little impact on clinical diagnostics
to date, but with the promise of the $1000 genome close
at hand,7 it seems only a matter of time before massively
parallel sequencing becomes routinely available in clinical
laboratories.
Massively parallel sequencing will allow simultaneous
screening for mutations in hundreds of loci in genetically
heterogeneous disorders, whole-genome screening for
novel mutations, and sequence-based detection of novel
pathogens that cause human disease. In addition,
massively parallel sequencing will permit clinical applica-
tion of our expanding knowledge of pharmacogenetics,
cancer genetics, epigenetics, and complex traits. As with
any new clinical test, analysis of clinical utility will have
to be undertaken and clear standards and guidelines will
need to be put in place before massively parallel sequenc-
ing can be routinely offered.
This review describes currently available massively
parallel sequencing platforms and their potential impact
on clinical testing in medical genetics, with consideration
of technical issues that pertain to clinical laboratories and
ethical issues that need to be addressed before massively
parallel sequencing can be incorporated into routine clin-
ical care.
Sanger Sequencing
Clinical DNA sequencing is currently performed by capil-
lary-based, semiautomated Sanger sequencing. DNA is
usually prepared by PCR ampliﬁcation of a region of
interest. The DNA is then sequenced by ‘‘cycle sequencing’’
that involves several rounds of template denaturation,
primer annealing, and extension (Figure 1).8 This ap-
proach can achieve read lengths of ~1 Kb and high accura-
cies at a cost of about $500 per megabase (Mb).9
Massively Parallel Sequencing Platforms
This section provides a brief overview of commercially
available massively parallel sequencing platforms. For
more detailed discussion of massively parallel platforms,
readers are referred to recent reviews.9,10
The Illumina Genome Analyzer, which uses ‘‘sequencing
by synthesis’’11,12 to produce single reads of 75þ basepairs
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Figure 1. Sanger Sequencing Workflow
DNA fragments are enriched by PCR and
sequenced with a combination of regular
deoxynucleotides and terminating labeled
dideoxynucleotides (ddNTPs), each with
a base-speciﬁc color. Different fragment
lengths are generated and size separated
by capillary electrophoresis, and the loca-
tion of each of the ddNTPs is identiﬁed
by excitation with a laser. Reprinted with
permission from Applied Biosystems.(Gb) of sequence in 7 days at a cost of ~$6 perMb (including
consumables, labor, instrument costs, and disc storage).10
The raw base accuracy is greater than 99.5% (Table 1).
The Applied Biosystems SOLiD Sequencer has read
lengths of up to 50 bp and produces 10–15 Gb of sequence
data in 3–7 days at a cost of ~$5.80 per Mb (including
consumables, labor, instrument costs, and disc storage).10
The raw base accuracy of the SOLiD System is 99.94%
(Table 1).13 This machine is unique in that it can process
two slides at a time; one slide is receiving reagents while
the other is being imaged. Each cycle of sequencing
involves the hybridization of ﬂuorescently labeled degen-
erate octomers to the DNA fragment sequence adjacent
to the universal primer’s 30 end.14 After several rounds of
ligation, the extended primer is removed and the process
is repeated with a universal primer that is offset by one
base from the adaptor-fragment position (Figure 3). Offset-
ting the universal primer in ﬁve sets of cycles permits the
entire fragment to be sequenced and provides an error-
correction scheme because each base position is queried
twice (once as a ﬁrst base and again as the second base in
the next or preceding set of cycles).9
The Roche GS-FLX 454 Genome Sequencer produces an
average read length of 400 bp and generates ~400–600 Mb
of sequence data per 10 hr run at a cost of $84.40 per Mb
(including consumables, labor, instrument costs, and disc
storage).10 The raw base accuracy of the 454 Genome
Sequencer is 99.5% (Table 1).13 The sequencing process
uses an enzymatic cascade to generate light from inorganic
phosphate molecules released by the incorporation of
nucleotides as the polymerase replicates the template
DNA (Figure 4).15
The Helicos machine sequences single molecules of DNA
without a prior ampliﬁcation step.16 Read lengths of 30–
35 bp are obtained, and 20–28 Gb of sequence are generated
in 8 dayswith a raw base accuracy greater than 99% (Table 1).
The price for this equipment is not currently available. A
highlysensitiveﬂuorescencedetectionsystemisusedto inter-
rogate each nucleotide directly as it is synthesized (Figure 5).
Other Technologies
There are a number of other technologies that are currently
under development, but these instruments are not yetThe Amercommercially available. One such approach by Paciﬁc
Biosciences uses Single Molecule Real Time (SMRT) DNA
sequencing. This method identiﬁes nucleotide incorpora-
tion by DNA polymerase into a single DNA strand.
Sequencing is performed on a chip containing thousands
of tiny holes tens of nanometers in diameter that function
as ‘‘zero-mode waveguides,’’ deﬁning the position at which
light released by replication of a single tethered DNAmole-
cule is detected. Nucleotides, each labeled through its
phosphate chain with a different colored ﬂuorophore,
and F29 DNA polymerase, a highly accurate and efﬁcient
enzyme,17 are added, and ﬂuorescent light characteristic
of each nucleotide is emitted as the DNA polymerase
copies the tethered single-stranded sequence. The DNA
polymerase cleaves the ﬂuorophore as each new base is
incorporated, returning the signal to baseline and permit-
ting the addition of another nucleotide.18
Another approach being developed by Oxford Nanopore
Technologies is nanopore sequencing. When voltage is
applied across a nanopore, an electrical current is created.
As a DNA fragment is electrophoretically pulled through
the nanopore, each base creates a unique change in the
magnitude of the electrical current.19 Other unique
massively parallel sequencing technologies are under
development by other companies, including Visigen
Biotechnology and Intelligent Biosystems. It is not clear
which massively parallel sequencing technologies will
gain greatest favor for clinical use, but it seems certain
that further reductions in the cost of sequencing and the
advantages conferred by these new technologies will
assure that massively parallel sequencing becomes an
essential clinical tool within the next decade.
Advantages of Massively Parallel Sequencing
Technology
The advantages and limitations of massively parallel
sequencing described below are presented in general terms,
but the technological differences among the systems may
make one particular massively parallel sequencing plat-
form more or less well suited for a speciﬁc application.
Sanger sequencing has been used for many different
applications, and improvements in chemistry, automa-
tion, and miniaturization over the years have permittedican Journal of Human Genetics 85, 142–154, August 14, 2009 143
it to be used for both small-scale (kilobase) and larger-scale
(megabase) projects. Despite these advances, it seems
unlikely that substantial further increases in throughput
or decreases in cost will be possible with Sanger sequencing
because of its dependence on lengthy procedures. The
ability of massively parallel sequencing to overcome these
limitations has allowed projects requiring many gigabases
of sequence to be performed much more quickly and less
expensively than with Sanger sequencing. For example,
massively parallel sequencing has permitted uncovering
Figure 2. Illumina Genome Analyzer Workflow
Sequencing libraries are generated by fragmenting genomic DNA,
denaturation, and adaptor ligation. Fragments are added to the
ﬂow cell chamber coated with oligonucleotides complementary
to the adaptors. Hybridization forms a ‘‘bridge,’’ and ampliﬁcation
is primed from the 30 end and continues until it reaches the 50 end.
After several rounds of ampliﬁcation, discrete clusters of frag-
ments, all with the same sequence, are formed. The clusters are
denatured, and sequencing primers, polymerase, and ﬂuorescently
labeled nucleotides, each with their 30OH chemically inactivated,
are added. After each base is incorporated, the surface is imaged,
the 30OH-inactivating residue and label are removed, and the
process repeated. Reprinted with permission from Illumina, Inc.144 The American Journal of Human Genetics 85, 142–154, Augusta vast amount of germline and somatic variation in normal
individuals.4,12
The increase in throughput and reduction in cost
achieved by massively parallel sequencing are a result of
three factors: (1)many thousands ormillions of sequencing
reactions are performed inparallel rather than just 1 to 96 at
a time, as in conventional sequencing machines and (2)
cloning or template ampliﬁcation of the DNA fragments
that are being sequenced is either unnecessary (in single-
molecule sequencing) or fully automated within the same
instrument that performs massively parallel sequencing.
Another advantage of massively parallel sequencing is
the ability to detect minor alleles accurately. Each DNA
fragment within the sequenced library is ampliﬁed and
sequenced (or in the single-molecule technologies, just
sequenced) independently of every other fragment, so if
a sample is mosaic, as is the case for most tumors, rare
somatic mutations can in principle be detected if depth
of sequence coverage is sufﬁcient. In addition, the ‘‘digital’’
nature of massively parallel sequencing means that the
number of times any particular DNA segment is sequenced
is proportional to the relative abundance of that segment
compared to all of the other segments in the original
sample. Thus, when a sample is sequenced to sufﬁciently
high depth, the copy number of any particular segment
can be inferred from the frequency with which that
segment is found among the molecules sequenced. With
conventional sequencing, rare mosaic variants may be
lost and heterozygous deletions cannot be detected
because sequencing is performed on the pool of templates,
rather than on single molecules.
Limitations of Massively Parallel Sequencing
Technology
All of the massively parallel sequencing platforms (except
454)produce read lengthsof50–100bp,whicharea fraction
of those obtained with current-generation Sanger se-
quencing machines. Short read lengths make de novo
sequence assemblymore difﬁcult and less complete, partic-
ularly for novel genomes or massively repetitive and rear-
ranged DNA segments. Short read lengths also complicate
interpretation in circumstances when it is necessary to
determine the phase of variants (e.g., recessively inherited
disorders). The implementation of paired-end or mate-
paired reads in massively parallel sequencing, which are
sequence reads from both ends of longer DNA molecules
of known length, permits the analysis of genomic frag-
ments up to 5–10 Kb in length, depending on the platform.
Paired-end reads have been used to identify single-nucleo-
tide mutations in Caenorhabditis elegans20 and structural
variants greater than 3 Kb in humans.3
Currently, the error rates of raw sequence data produced
by all of the massively parallel sequencing platforms are
higher than with Sanger sequencing, but the overall error
rate is reduced because of the high degree of sequencing
depth, typically 40-fold for a diploid genome, that is neces-
sary to achieve complete coverage with massively parallel14, 2009
Table 1. Comparing Massively Parallel Sequencing Technologies
Sequencing Chemistry Amplification Approach Read Length Run Time and Throughput Raw Accuracy Cost
Illumina polymerase-based
sequencing by synthesis
bridge PCR 75þ bp 17 Gb in 7 days 98.5% $6/Mb
SOLiD ligation-based emulsion PCR 50 bp 10–15 Gb in 3-7 days 99.94% $5.80/Mb
454 pyrosequencing emulsion PCR 400 bp 400–600 Mb in 10 hr 99% $84.40/Mb
Helicos polymerase-based none (single-molecule sequencing) 30–35 bp 21–28 Gb in 8 days 99% not availablesequencing. Higher coverage is especially important when
looking for mutations or sequence variants in repetitive or
massively rearranged regions.21,22 However, greater depth
means more sequencing, thereby reducing the advantages
of using massively parallel sequencing.
For clinical applications, there is a great need to increase
the accuracy of raw massively parallel sequencing data.
The introduction of a proof-reading polymerase in the
sequencing process might increase the raw accuracy rate.
The development of algorithms that take into account
the data quality whenmaking a base call23–26 will no doubt
be useful as well. These efforts will be enhanced by the
development of standardized quality metrics for se-
quencing results, similar to those that have been imple-
mented for microarray testing.9 These include measures
of (1) technical reproducibility, (2) distribution of esti-
mated accuracies for raw base calls, (3) systematic error
patterns in raw or consensus sequence data, and (4) bias
and skewing of true ratios in tag counting applications.9
It will be the responsibility of clinical laboratories that
use massively parallel sequencing to include such quality
metrics in their reports. This will not only permit standard-The Amerization within the laboratory but also facilitate comparison
of test results between different laboratories.
As with any new technology, the initial costs necessary
to set up a massively parallel sequencing platform are
high. Commercially available instruments cost $400,000–
$1,350,000 each, and there are also costs associated with
the software, training, and data transfer and storage
required for the vast quantity of data generated by
massively parallel sequencing platforms. In addition,
massively parallel sequencing data interpretation requires
much greater bioinformatic expertise than is available in
most clinical laboratories. In recent years, a growing
number of programs that vary in function and user-friend-
liness have been designed to align short read sequences to
a reference and provide accurate base calling.9 In order
for clinical laboratories to adopt massively parallel
sequencing, it will be necessary to develop data analysis
and interpretation software that is geared toward clinical
testing and that can be used by technicians and laboratory
directors who do not have a background in bioinformatics.
Whole-genome sequencing is not yet practical in the
clinical setting, and it is likely that massively parallelFigure 3. Applied Biosystems SOLiD Sequencer Workflow
DNA is fragmented and oligonucleotide adaptors are ligated to each end. The fragments are hybridized to complementary oligonucle-
otides attached to magnetic beads. The beads are contained within an oil emulsion where ampliﬁcation is performed. When ampliﬁca-
tion is complete, the emulsion is broken, and the beads are attached to a glass surface and placed within the sequencer. A universal
sequencing primer, complementary to the adaptor sequence, is added followed by subsequent ligation cycles with ﬂuorescently labeled
degenerate octomers. After each cycle, the glass surface is imaged and the octomer is cleaved between bases 5 and 6, removing the ﬂuo-
rescent tag, and a new octomer is added. After several rounds of sequencing, the extended universal primer is removed and a new
universal primer is added that is offset by one base. Reprinted with permission from Applied Biosystems.ican Journal of Human Genetics 85, 142–154, August 14, 2009 145
Figure 4. GS-FLX 454 Sequencer Workflow
DNA is fragmented and adaptors, one of which is biotinylated, are ligated to each end. Fragments are coupled to agarose beads by oligo-
nucleotides complementary to the adaptor sequence and containedwithin an emulsion droplet for ampliﬁcation.When ampliﬁcation is
completed, the beads are put into an individual well on a ﬁber optic slide and placed in the sequencer. Nucleotides and polymerase are
sequentially added, and the sequence produced is monitored by the generation of light through an enzymatic reaction that is coupled to
DNA synthesis. Modiﬁed with permission from 454 Sequencing, copyright 2009 Roche Diagnostics.sequencing will initially be used to sequence selected
genomic regions. Potential applications, which are dis-
cussed in more detail below, include testing many different
loci formutations simultaneously in a patient with a genet-
ically heterogeneous disease or screening a large number of
samples formutations in a set of candidate genes. The latter146 The American Journal of Human Genetics 85, 142–154, Augustis made possible by molecular ‘‘barcoding,’’ which involves
adding a short DNA sequence tag that is unique to a partic-
ularpatient toeveryDNAfragmentmade fromthatpatient’s
sample. Several patient samples can then be pooled and
sequenced together, and the sequences obtained from
each patient can be separated bioinformatically.27Figure 5. Helicos Heliscope Sequencer
Workflow
Fragments are captured by poly-T oligo-
mers tethered to an array. At each
sequencing cycle, polymerase and single
ﬂuorescently labeled nucleotide are added
and the array is imaged. The ﬂuorescent
tag is then removed and the cycle is
repeated. Reprinted with permission from
Helicos BioSciences Corporation.14, 2009
Figure 6. Genomic Enrichment Strategies
(A) Megaplex PCR. Surface-bound oligonucleotide primers (F & R) bind to DNA and amplify the sequence for the 1st and 2nd round of
PCR. This reaction also incorporates a sequence that is complementary to a universal primer (U1 & U2), which is used for subsequent
PCR cycles. Modiﬁed from ten Bosch and Grody.13
(B) Selector Probe Circularization. Genomic DNA (gray) is digested with restriction enzymes and circularized by hybridization of
‘‘selector probes’’ (black) with single stranded overhangs (white box) to the 30 and 50 ends of the digested DNA. DNA ligase ﬁlls in the
gap, and universal primers (checkered box), complementary to the sequences within the selector probes, are used to amplify the circu-
larized DNA. Modiﬁed from ten Bosch and Grody.13
(C) Nested-Patched PCR. Primer pairs containing uracil instead of thymine (wide white arrow) are constructed for all target regions. The
primers amplify target regions for a low number of cycles. The primers are cleaved with uracil DNA glycosylase, nested patch oligonu-
cleotides (gray and white checkered box) are annealed to target amplicons, universal primers (gray box) are ligated to the amplicons, and
subsequent PCR cycles are primed with these universal primers. Modiﬁed from Varley and Mitra.27
(D) Microarray pull-downmethod. Genomic DNA is fragmented, and universal adaptor (white box) sequences are ligated to the ends of
each fragment. The fragments of interest are captured by hybridization on the microarray (black line), which has been constructed with
probes that are complementary to these sequences. The array is then denatured, and the fragments released are enriched by PCRwith the
universal adaptor sequence as primers. Modiﬁed from ten Bosch and Grody.13Targeted sequencing requires substantial up-front prepa-
ration to select the DNA segments of interest. PCR with
modiﬁcations to permit higher multiplexing is one useful
way to do this. Examples of some available methods
are shown in Figures 6A–6C. Such methods have been
used to amplify hundreds of selected exons from a DNA
sample.27–29
Alternatively, targeted regions can be obtained by direct
hybridization to oligonucleotide arrays containing probes
complementary to the regions of interest. The array isThe Amerthen denatured, and the fragments obtained can be ampli-
ﬁed or directly sequenced, depending on the depth of
hybridization (Figure 6D). Thismethod has been successful
on a large number of target regions with both the 454 FLX
Sequencer30 and the Illumina Genome Analyzer.31–34
Several other novel methods have recently been developed
to enrich segments of interest.35–37 However, any enrich-
ment strategy is unlikely to be effective for all genomic
applications, highlighting the importance of further devel-
opment of enrichment techniques.ican Journal of Human Genetics 85, 142–154, August 14, 2009 147
Interpretation of Data
Six billion base pairs of DNA per patient are a lot of data to
interpret. Computers and software can help—in fact, they
are essential—but clinical interpretation of genome
sequence data will always require a well-trained and expe-
rienced genetics professional. As a practical matter, only
a subset of a person’s genome can actually be examined
for variants that cause or predispose to disease. This subset
may either be selected before sequencing is done with
a technique like those described in the previous section
or, if whole-genome sequencing is performed, bioinfor-
matically after all of the sequence data have been obtained.
In either case, clinical sequencing requires decisions
regarding what subset of the genome will be examined.
The subset examined for a particular patient may be
different under different circumstances. If the goal is to
obtaingenotypesof a comprehensive setof single-nucleotide
polymorphisms (SNPs), copy-number variants (CNVs), and
other structural variants (SVs) for disease prediction, itwould
make most sense to focus on these polymorphic regions. If
the goal is to identify a sequencemutation inanunidentiﬁed
locus, sequencing all exons and adjacent promoter regions
may be most informative. If the goal is to survey a more
limited subset of loci for rare sequence mutations and copy
number changes that are known to produce a genetically
heterogeneous condition such as autism, a more targeted
approach may be optimal. In other circumstances, such as
identifying pathogenic mutations in patients with intellec-
tual disability, it may be most productive to pursue a hybrid
strategy that might include sequencing paired-end reads to
assess copy number variation genome-wide as well as selec-
tive sequencing of all exons of loci known to cause recessive
forms of intellectual disability.
Any selection process will be incomplete, and the possi-
bility will always exist that a genetic variant outside the
region examined in detail is actually pathogenic in the
patient who is being tested. This would argue for the use
of liberal inclusion criteria to select the genomic subset
thatwill be analyzed in detail. On the other hand, the larger
the fraction of the genome assessed, the greater the number
of genetic variants that will have to be evaluated for patho-
genicity indetail and themore likely that genetic variants of
uncertain clinical signiﬁcance will be encountered.
Variants encountered on sequencing may be of several
kinds.38 Some are known on the basis of extensive clinical
experience to be pathogenic or, alternatively, not to be
associated with disease. In many other instances, clinical
experience with a particular variant is insufﬁcient to
provide an unequivocal interpretation with respect to
pathogenicity, and other factors have to be considered.
Such variants include:
d Those that are unreported but likely to be causative as
determined by the type of mutation (e.g., mutations
that create a stop codon or cause a frame shift);
d Those that are unreported and may or may not be
causative of disease, including mutations that148 The American Journal of Human Genetics 85, 142–154, August 1generate a cryptic splice site or are likely to affect tran-
scription;
d Those that are unreported and are less likely to be
causative of disease because they do not produce an
amino acid change in the encoded protein.
Unfortunately, however, the pathogenicity of a sequence
change sometimes cannot be predicted from its inferred
effect on a gene’s protein product. For example, a recent
study that used Sanger sequencing to screen 718 coding
exons on the X chromosome in 208 families with X-linked
intellectual disability demonstrated that protein trun-
cating variants, which usually result in loss of protein func-
tion and are a frequent cause of Mendelian diseases, occur
in at least 1% of the X chromosome genes without any
effect on normal intellectual ability.39
Disease- or locus-speciﬁc databasesmaybeveryhelpful in
determining whether a variant identiﬁed in a patient is
causative of a particular disease. However, most of these
databases are not designed to meet clinical standards, and
they vary greatly in their completeness, rigor of interpreta-
tion, and currency. Critical information found in a database
should be checked against the original source, and correla-
tion of genomic ﬁndings with detailed phenotypic infor-
mation on individual patients is essential.7,40,41 Clinical
sequencing will result in an explosion of data on variants,
both pathogenic and benign, and clinical laboratories can
improve their ability to interpret future data by carefully
tracking their own patients in a local database and contrib-
uting both genotype and phenotype information to
publicly available collaborative databases.
Genotyping of other family members is often very help-
ful in assessing pathogenicity, especially in the case of
dominant diseases for which the presence of a mutation
in an affected child and its absence in the normal parents
suggests that the variant is causal. Functional testing of
mutations is an effective means of determining pathoge-
nicity of a given mutation but is beyond the scope of
most clinical laboratories. Nevertheless, collaboration of
clinicians, clinical laboratories, and research laboratories
to perform functional studies is essential to the progress
of clinical genetics.
Applications in Clinical Genetics Labs: Improvements
in Current Diagnostic Capabilities
Sanger sequencing has been used clinically in conjunction
withPCR formore thanadecade to identify sequencemuta-
tions and other variants of selected Mendelian disease
genes, but wider application of sequencing to clinical
testing has been limited by cost and throughput. More
recently, many clinical genetics laboratories have adopted
array genomic hybridization as a means of detecting copy
number changes that cause intellectual disability and other
birth defects. Here we consider how massively parallel
sequencing could be used to perform these and other forms
of genetic testing that are currently available clinicallymore
cost effectively and with higher throughput.4, 2009
Mutation Detection in Mendelian Disease
Massively parallel sequencing could be used to sequence
very large as well as smaller Mendelian disease genes fully,
covering all exons as well as the associated 50, 30, and in-
tronic sequences. This improved coverage could increase
the sensitivity ofmutation detection over currentmethods,
which often employ a screening technique such as SSCP
prior to sequencing and limit the segments sequenced to
the exons that are most frequently affected by mutations
or, at best, just to the exons and the immediately
surrounding bases.30,32,42 However, the capacity of current
massively parallel sequencing platforms is too great for efﬁ-
cient sequencing ofmost single genes. For example, a single
lane on an Illumina ﬂow cell would providemore than 683
coverage of the entire genomic segment containing the
DMD gene (MIM #300377) in a male. A solution to this
problemwould be to pool DNA samples from several family
members or from unrelated patients that have been
prepared by locus-speciﬁc PCR and barcoded so that the
DNA from each individual can be distinguished.27
Recognizing Disease Predisposing and Protective Factors
Massively parallel sequencing has distinct advantages as
a means of recognizing variants that may predispose to,
or protect against, the development of common complex
diseases. SNP arrays, even those with millions of features,
provide genotypes of only a small fraction of the variants
present in an individual. In contrast, massively parallel
sequencing could provide complete information on all
SNPs and other disease-associated variants that are present.
This may be especially important in people whose origin is
not from a population for which the tag-SNPs on most
genotyping arrays provide optimal coverage. In addition,
massively parallel sequencing could detect rare variants
as well as the common ones for which genotyping chips
are designed, and rare variants may be especially important
in recognizing people with predispositions to developing
certain complex diseases.43,44
Pharmacogenomics
Adverse drug reactions are one of the leading causes of death
and illness.45 Although many factors contribute, it is clear
that genetic variation plays a key role in adverse reaction to
drugs as well as to differences in the effectiveness of drug
treatments. A goodexample ofusingpharmacogenetics clin-
ically is testing for CYP2C9 (MIM #601130) and VKORC1
(MIM #607473) variants conjointly to determine dose
requirements and hence susceptibility to adverse drug reac-
tions related to warfarin.46–49 Sequencing could permit the
identiﬁcation of these and all other pharmacogenetic vari-
ants (once we know them) in a single assay, thus permitting
trulypersonalizeddrug treatment.Thiswouldbeparticularly
valuable for many elderly patients and others with chronic
diseases who must take manymedications concurrently.
Improved Diagnosis and Treatment of Cancer
Somatic mutations of various kinds are present in almost
all cancers. Microarray testing provides a useful means ofThe Amersurveying the entire genome for loss of heterozygosity
and gene ampliﬁcation,50–52 and specialized molecular
tests have been developed to assay for mutations and
fusion genes produced by translocations that are associ-
ated with particular subtypes of cancer.53,54 Massively
parallel sequencing could provide information simulta-
neously on copy number changes, sequence mutations,
and fusion genes anywhere in the genome that are associ-
ated with the development of malignancy.55
Cancer genomes are very heterogeneous because of the
genetic instability and clonal evolution that characterize
tumor development. Moreover, most tumors are composed
of several different types of cells, some of which may not be
part of the malignant clone. Consequently, mutations
involved in tumor development or progression may be
present inonlya small fractionof the cells andmaybemissed
with array studies and PCR-based assays of whole-tumor
DNA.Massivelyparallel sequencingcouldaccuratelymeasure
cancer-associatedgeneticalterationsthatoccur inonlyasmall
fractionof thecells testedbecause the independentampliﬁca-
tion and sequencing of millions of different DNA fragments
from each specimen permits the accurate detection of rare
sequences if the depth of coverage is sufﬁcient.
Epigenetics
Somatic epigenetic changes are important in the develop-
ment of some cancers56 and constitutional epigenetic
abnormalities cause congenital anomaly syndromes such
as pseudohypoparathyroidism (MIM #612463),57 Wiede-
mann-Beckwith syndrome (MIM #130650),58 and Russell-
Silver syndrome (MIM #180860).59 Current clinical assays
can demonstrate epigenetic alterations in individual genes,
but massively parallel sequencing could be used to
perform genome-wide tests of epigenetic changes that
are known to cause particular disease states. For exam-
ple, bisulﬁte sequencing was recently combined with
massively parallel sequencing to examine methylation
patterns throughout the genome in hematopoietic
tumors,60 and histone modiﬁcations have been identiﬁed
genome-wide by combining chromatin immunoprecipita-
tion with massively parallel sequencing.61,62
Identification of Structural Variants
Structural variants (SVs) include copy number variants
(CNVs) as well as inversions and other chromosomal rear-
rangements that do not involve a change in copy number.
Most CNVs occur as benign polymorphisms, but pathogenic
CNVshaverecentlybeenfoundtobe themost frequent recog-
nizable cause of intellectual disability and some other birth
defects.63,64 Array genomic hybridization is now used clini-
cally to detect such pathogenic CNVs, but this technology
does not detect balanced SVs. Other CNVs are involved in
modulationof complex traits65 anddisease susceptibility.66,67
Massively parallel sequencing can reliably identify both
balanced and unbalanced SVs68 and provides much higher
resolution than is possible with array genomic hybridization,
permitting better genotype-phenotype correlation.ican Journal of Human Genetics 85, 142–154, August 14, 2009 149
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Figure 7. Paired-End Reads
DNA is isolated (A), fragmented into pieces of a standard size, e.g., about 3 kb, and ligated to adaptors (blue boxes) on both ends (B).
Adaptors permit 3 kb pieces to be circularized (C). Circles are isolated, then broken into much smaller fragments (e.g., a few hundred
base pairs) (D), and the fragments containing adaptors are isolated. In these fragments, the adaptor is ﬂanked by the sequence that
was at the opposite ends of the original 3 kb piece. The paired ends are sequenced and mapped back to the canonical human genome
(E) so that structural variants can be identiﬁed (see text).The short reads of most current massively parallel
sequencing platforms limit their ability to map structural
variants to the single-base-pair level because many short
segments occur more than once in the genome and cannot
be mapped uniquely. Mapping each segment to a unique
genomic position is necessary to recognize balanced SVs
and to count how many times each fragment or portion
thereof appears in the original DNA sample. One solution
to this problem is to use paired-end reads. DNA is frag-
mented in a manner that produces pieces of known size,
and both ends of each fragment are ligated to adaptors,
permitting circularization. The DNA circles containing
the adaptors are then broken intomuch smaller fragments.
A few of these smaller fragments include the adaptors
ﬂanked on either side by the DNA that lay on opposite
ends of the original larger DNA fragment (Figure 7). These
small fragments containing the adaptors and ‘‘paired-end
tags’’ are then isolated, and the sequence at both ends is
determined. Mapping these ‘‘paired-end reads’’ back to
the canonical human genome sequence permits recogni-
tion of deletions as pairs of reads that map further apart
than expected given the known length of the original frag-
ment, duplications as pairs of reads that map closer to each
other than expected given the length of the original frag-
ment, inversions as pairs of reads that have a different
orientation from the original fragment, and rearrange-
ments as pairs that are not expected to lie together on
the original fragment at all. Paired-end reads obtained by
massively parallel sequencing have been used to map 853
deletions, 322 insertions, and 122 inversions identiﬁed150 The American Journal of Human Genetics 85, 142–154, Augustin two individuals to an average breakpoint resolution of
644 bp in one recent study.3
Novel Diagnostic Capabilities by Massively Parallel
Sequencing
The following discussion focuses on applications that are
now being conducted in research laboratories but are not
currently performed routinely, if at all, in clinical laborato-
ries. Massively parallel sequencing offers the opportunity
to implement these two applications as new clinical
services. There are, of course, many other potential appli-
cations for massively parallel sequencing in clinical
research, such as genome-wide association studies and
linkage studies, but this discussion is limited to the appli-
cations that seem most likely to be used on a routine clin-
ical basis in the next several years.
Simultaneous Screening for Mutations at Multiple Loci
Some conditions that are seen frequently by clinical geneti-
cistsmaybecausedbyMendelianmutationsofmanydozens
orhundreds of different genetic loci. Examples include intel-
lectual disability, deafness, familial cardiomyopathy, and
retinitis pigmentosa. The current approach to identifying
the causal mutation in a particular family involves recogni-
tionof a phenotypic subset thatmay bemore or less speciﬁc,
thenmutation testing a series of genetic loci, individually or
in small sets, based on the relative frequency of the muta-
tions and the sensitivity of available assays. If there is no
predominant mutation, as is the case for intellectual14, 2009
disability, for example, this testing, nomatter howextensive
(and expensive), often fails to ﬁnd thepathogenicmutation.
Massively parallel sequencing could provide the oppor-
tunity to test hundreds or even thousands of candidate
loci simultaneously. This could be done by whole-genome
sequencing and selective bioinformatic analysis or by
sequencing candidate regions selected by array capture or
one of the other methods of targeted ampliﬁcation
described above (Figure 6).
Metagenomics
Metagenomics is the brute force sequencing and bioinfor-
matic analysis of DNA fragments obtained from an uncul-
tured, unpuriﬁed microbial and or viral population.
Humans live in symbiosis with billions of bacteria that
inhabit both the outer and inner surfaces of our bodies
(skin, respiratory tract, etc.).69 These microorganisms are
essential for our health, and alterations of their numbers or
types can cause disease.70,71 Massively parallel sequencing
could provide the ability to recognize previously unidenti-
ﬁedmicroorganisms that are associated with human disease
by mass sequencing of an infected tissue or ﬂuid, bioinfor-
matically ‘‘subtracting out’’ all human sequences, recog-
nizing the sequences of normal commensal organisms,
and then analyzing what is left to identify the unknown
pathogen. Longer paired-end reads could facilitate the de
novo sequence assembly of the unknown pathogen by ﬁrst
mapping the smallest fragments onto larger fragments and
then assembling the larger fragments into a whole genome
sequence. The ability of massively parallel sequencing to
characterize rare DNA fragments accurately and the ability
to assemble de novo sequences via overlapping reads could
permit the identiﬁcation of a tiny amount of microbial
DNA in the presence of a vast excess of humanDNA. Several
important advances have recently been achieved with this
technology, including the identiﬁcationofpreviouslyunrec-
ognized microorganisms that are associated with a fatal
febrile illness in organ transplant recipients,72 infant diar-
rhrea,73 and a variety of other gastrointestinal diseases.71
Ethical Considerations
Massively parallel sequencing technology is rapidly
advancing and is likely to enable these and other routine
clinical applications in the near future. However, massively
parallel sequencing, and especially whole-genome se-
quencing, raises a number of important ethical issues that
need tobe resolvedprior to routine clinical implementation.
None of these issues are unique to clinicalmassively parallel
sequencing—all have been raised before in the context of
genetic testingandotheraspects of clinical geneticspractice.
Nevertheless, clinicaluseof thisultimategenetic technology
raises these issues all at once and brings them into sharp
focus. The huge amount of personal medical data produced
bymassively parallel sequencing, the fact thatmost of it will
be irrelevant to anyparticular clinical problembutmaybeof
importance to the patient in other ways or in the future, our
inability to interpretmuchof thedata, and the ability to linkThe Amerthe information to an individual person despite the
complete absence of any conventional personal identifying
information all require careful consideration and the devel-
opment of appropriate rules or guidelines prior to clinical
implementation. The ethical issues raised by clinical use of
massively parallel sequencing include the following:
d Consent
d Does whole-genome sequencing require a different
level or kind of consent than other genetic tests or
medical assessments?
d Should whole-genome sequencing be done when
the same question can be answered bymore limited
(e.g., locus-speciﬁc) testing?
d Should whole-genome sequencing be done in chil-
dren or incompetent adults?
d Is informed consent for whole-genome sequencing
possible?
d Interpreting Sequence Data
d Should patients be informed of results of uncertain
clinical signiﬁcance?
d Should patients be informed of results that predict
serious disease that cannot be prevented or treated?
d Should patients be informed of results that do not
have direct implications for them but do for other
family members?
d Should other family members be informed of ﬁnd-
ings that have direct implications for them that
were found on analysis of a relative’s genomic
sequence?
d The Rest of the Data
d Should patients be informed of incidental ﬁndings
that unequivocally predict serious disease that can
be prevented or ameliorated by early detection?
What if the disease cannot be prevented or amelio-
rated?
d Should patients be informed of incidental ﬁndings
that indicate an increased (or reduced) risk for
disease that can be prevented or ameliorated by
early detection? What if the disease cannot be pre-
vented or ameliorated?
d Should physicians or clinical laboratories provide
genomic information that has no medical impor-
tance but is of social or personal consequence to
the patient (e.g., ancestry or paternity)?
d Should physicians or clinical laboratories provide
genomic information that has no medical impor-
tance but is of general interest to the patient
(e.g., SNPsassociatedwithathleticormusical ability)?
d Is it appropriate to generate whole-genome data
that may or may not be of clinical signiﬁcance
but analyze only a small portion of those data to
answer a speciﬁc clinical question?
d Do physicians or clinical laboratories have a duty to
recontact patients if sequence data that were previ-
ously obtained are later found to have serious
medical implications?ican Journal of Human Genetics 85, 142–154, August 14, 2009 151
d Storing Sequence Data
d Do physicians or clinical laboratories have a respon-
sibility to retain a patient’s genomic data for long
periods of time (or throughout life) in case future
reanalysis is necessary?
d Where should individual sequence data be stored,
and who should be responsible for the stored data?
d Who should be able to obtain access to an individ-
ual’s complete genomic sequence? The individual?
Any treating physician? Insurance companies?
Police (e.g., for criminal investigations)?
d Under what circumstances should stored genomic
data be used for purposes of identiﬁcation (e.g.,
for identiﬁcation of disaster victims or conﬁrma-
tion of citizenship)?
Conclusion
It is very likely that incremental improvements in
currently available massively parallel sequencing technol-
ogies or the introduction of others that are currently in
development will make sequencing an individual patient’s
entire genome at sufﬁcient depth to identify almost all
mutations and genetic variants practical for routine clin-
ical applications in the near future. In order for massively
parallel sequencing to be implemented clinically, the accu-
racy of sequencing needs to be increased and improve-
ments in the methods available for selecting particular
genomic subsets and for bioinformatic analysis of huge
amounts of raw sequence data are necessary, but rapid
progress is being made in these areas. The $10 million
Archon X Prize for the ﬁrst team to sequence 100 human
genomes in 10 days may be won within the next year.
Clinical laboratory scientists, genetic counselors, clinical
geneticists, and other physicians all must learnmuchmore
about this technology and its clinical application to use
massively parallel sequencing safely and effectively. There
is an urgent need for translational research regarding the
clinical validity and clinical utility of massively parallel
sequencing data,74 as well as for professional education
regarding the value, limitations, and appropriate clinical
use of this powerful new technology.
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